Interstate Advanced Materials delivers conduit and duct support system material solutions designed for long-term performance in underground environments.

Furthermore, the endothelialized conduit inwardly remodeled at corners, yielding a more physiologic, rounded cross-section. As well, basement membrane proteins were elaborated on the basal endothelial ...

Humacyte's Symvess shows economic value in vascular repair, potentially reducing hospital costs, according to a new publication.

The principles of vascular tissue engineering outlined over the last decade, guides through the fabrication of biopolymer based vascular scaffolds in this study. Favorable hemocompatibility, ...

Humacyte's Symvess approval signals growth in regenerative medicine. See why HUMA stock is not yet a buy as we monitor its trajectory in regenerative medicine.

This post will delve into the Schedule 80 conduit, exploring its benefits, applications, installation, and why it's the go-to choice for contractors or experts.

Xeltis announced today that it completed enrollment in an EU pivotal trial for aXess, its restorative vascular access conduit.

DURHAM, N.C. - The U.S. Food and Drug Administration (FDA) has granted full approval to Humacyte, Inc.'s SYMVESS for use in adults requiring vascular conduit for extremity arterial injury when urgent ...

Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair in trauma cases.

“The approval of a vascular conduit that resists infection and remodels into native arteries is an extraordinary technological advancement that will have a huge impact on the quality of trauma ...

Introduction: Patients with single ventricle disease and Fontan circulation suffer long-term morbidity due to the lack of a sub-pulmonary ventricle. The concept of a pulsatile Fontan conduit, ...